Rosacea and its management: An overview

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 3, 2005, Pages 273-285

  Gupta, A K ^a,b,c   Chaudhry, M M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

Azelaic acid; Isotretinoin; Management; Metronidazole; Rosacea; Tetracycline

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZELAIC ACID; BENZYL BENZOATE; CLARITHROMYCIN; CLINDAMYCIN PHOSPHATE; CLONIDINE; COSMETIC; CROTAMITON; DOXYCYCLINE; GLYCOLIC ACID; HYDROCORTISONE; HYDROQUINONE; ISOTRETINOIN; LINDANE; LYMECYCLINE; METRONIDAZOLE; NADOLOL; NALOXONE; OXYTETRACYCLINE; PERMETHRIN; PLACEBO; RETINAL; RETINOIC ACID; SULFACETAMIDE; SULFUR; TETRACYCLINE; TRIACYLGLYCEROL;

ARGON LASER; BEHAVIOR MODIFICATION; BLEPHARITIS; BONE PAIN; CAUCASIAN; CAUTERIZATION; CHEILITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CRYOSURGERY; DEMODEX; DERMATITIS; DIET RESTRICTION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRY NOSE; ELECTROSURGERY; ERBIUM YAG LASER; EUROPE; EXCISION; FAMILY HISTORY; FLUSHING; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; LASER SURGERY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; META ANALYSIS; MYALGIA; NAUSEA; NEODYMIUM LASER; NONVERBAL COMMUNICATION; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; PUSTULE; REMISSION; REVIEW; ROSACEA; SELF CONCEPT; SKIN ABRASION; SYSTEMATIC REVIEW; TELANGIECTASIA; TINNITUS; TREATMENT FAILURE; XEROSTOMIA;

HUMANS; ROSACEA;

EID: 18844450450     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01216.x     Document Type: Review

References (86)

1. Gratton D. The many faces of rosacea. J Cut Med Surg 1998; 2 (Suppl. 4): 2-4.
2. Jansen T, Plewig G. Rosacea: classification and treatment. J R Soc Med 1997; 90: 144-150.
3. Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-587.
4. Singer MI. Drug therapy of rosacea: a problem-directed approach. J Cutan Med Surg 1998; 2 (Suppl. 4): 20-23.
5. National Rosacea Society. Survey finds that rosacea flare-ups are common but can be controlled [online]. Spring 1999 Rosacea Review. Available from URL: http://www.rosacea.org/99spart3.html/.
6. Millikan L. Recognizing rosacea. Could you be misdiagnosing this common skin disorder? Postgrad Med 1999; 105: 149-158.
7. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983; 119: 211-214.
8. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989; 20: 202-205.
9. Bernstein JE, Soltsni K. Alcohol-induced rosacea flushing blocked by naloxone. Br J Dermatol 1982; 107: 59-61.
10. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol 1993; 32: 65-67.
11. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78: 649-652.
12. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 1971; 2: 1049-1052.
13. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 1997; 36: 942-946.
14. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980; 102: 443-445.
15. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976; 1: 1211-1212.
16. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 1994; 130: 319-324.
17. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol 1986; 25: 660-663.
18. Turjanmaa K, Reunala T. Isotretinoin treatment of rosacea. Acta Derm Venereol 1987; 67: 89-91.
19. Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol 1984; 9: 484-488.
20. Erdogan FG, Yurtsever P, Aksoy D et al. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea [letter]. Arch Dermatol 1998; 134: 884-885.
21. Blom I, Hornmark AM. Topical treatment with sulfur 10 per cent for rosacea. Acta Derm Venereol 1984; 64: 358-359.
22. Monk BE, Logan RA, Cook J et al. Topical metronidazole in the treatment of rosacea. J Dermatol Treat 1991; 2: 91-93.
23. Veien NK, Christiansen JV, Hjorth N et al. Topical metronidazole in the treatment of rosacea. Cutis 1986; 38: 209-210.
24. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 1983; 109: 63-65.
25. Schachter D, Schachter RK, Long B et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Invest 1991; 3: 220-224.
26. Thiboutot DM. Acne rosacea. Am Fam Physician 1994; 50: 1691-1697.
27. Aronson IK, Rumsfield JA, West DP et al. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm 1987; 21: 346-351.
28. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol 1987; 123: 609-614.
29. Lowe NJ, Henderson T, Millikan LE et al. Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial. Cutis 1989; 43: 283-286.
30. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol 1998; 39: 502-504.
31. Bjerke JR, Nyfors A, Austad J et al. Metronidazole (Elyzol*) 1% cream vs. placebo cream in the treatment of rosacea. Clin Trials 1989; 26: 187-194.
32. Bitar A, Bourgouin J, Doré N et al. A double-blind randomized study of metronidazole (Flagyl®) 1% cream in the treatment of acne rosacea: a placebo-controlled study. Drug Invest 1990; 2: 242-248.
33. Breneman DL, Stewart D, Hevia O et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 1998; 61: 44-47.
34. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol 1983; 108: 327-332.
35. Dahl MV, Jarratt M, Kaplan D et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol 2001; 45: 723-730.
36. Tan JKL. A new formulation containing sunscreen (SPF 15) and 1% metronidazole (Rosasol® Cream) in the treatment of rosacea. Skin Ther Let 2001; 6: 1-2.
37. Tan JKL, Girard C, Krol A et al. Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. J Cut Med Surg 2002; 6: 529-534.
38. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999; 40: 961-965.
39. Metronidazole lotion 0.75% (Metrolotion™) package insert. Physicians' desk reference. Montvale, Medical Economics Company, 2000: 1106-1107.
40. Signore RJ. A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Cutis 1995; 56: 177-179.
41. Kocak M, Yagli S, Vahapoglu G et al. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 2002; 205: 265-270.
42. Sauder DN, Miller R, Gratton D et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat 1997; 8: 79-85.
43. Lebwohl MG, Medansky RS, Russo CL et al. The comparative efficacy of sodium sulfacetamide 10%/Sulfur 5% (Sulfacet-R®) Lotion and Metronidazole 0.75% (MetroGel®) in the treatment of rosacea. J Geriatr Dermatol 1995; 3: 191-195.
44. Vienne MP, Ochando N, Borrel MT et al. Retinaldehyde alleviates rosacea. Dermatol 1999; 199 (Suppl. 1): 53-56.
45. Carmichael AJ, Marks R, Graupe KA et al. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat 1993; 4: S19-S22.
46. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol 1999; 79: 456-459.
47. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48: 836-845.
48. Dahl MV. Pathogenesis of Rosacea. In: James WD, ed. Advances in Dermatology, 17th edn. Mosby, Inc., 2001: 29-45.
49. Wilkin JK, Rosacea. Pathophysiology and treatment. Arch Dermatol 1994; 130: 359-362.
50. Dahl MV, Katz HI, Krueger GG et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998; 134: 679-683.
51. Arndt KA. Argon laser therapy of small cutaneous vascular lesions. Arch Dermatol 1982; 118: 220-224.
52. Apfelberg DB, Maser MR, Lash H et al. Expanded role ofthe argon laser in plastic surgery. J Dermatol Surg Oncol 1983; 9: 145-151.
53. Dicken CH. Treatment of the red nose with the argon laser. Mayo Clin Proc 1986; 61: 893-895.
54. West TB, Alster TS. Comparison of the long-pulse dye (590-595 nm) and KTP (532 nm) lasers in the treatment of facial and leg telangiectasias. Dermatol Surg 1998; 24: 221-226.
55. Mark KA, Sparacio RM, Voigt A et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg 2003; 29: 600-604.
56. Laughlin SA, Dudley DK. Laser therapy in the management of rosacea. J Cutan Med Surg 1998; 2 (Suppl. 4): 24-29.
57. Hoasjoe DK, Stucker FJ. Rhinophyma: review of pathophysiology and treatment. J Otolaryng 1995; 24: 51-56.
58. Wiemer DR. Rhinophyma. Clin Plast Surg 1987; 14: 357-365.
59. Riefkohl R, Georgiade GS, Barwick WJ et al. Rhinophyma: a thirty-five-year experience. Aesthetic Plast Surg 1983; 7: 131-134.
60. Goldstien JA, Conite H, Mercon H et al. Isotretinoin in the treatment of acne. Arch Dermatol 1982; 118: 555-558.
61. Har-El G, Shapshay SM, Bohigian RK et al. The treatment of rhinophyma: 'cold' vs laser techniques. Arch Otolaryngol Head Neck Surg 1993; 119: 628-631.
62. Sonnex TS, Dawber RPR. Rhinophyma-treatment by liquid nitrogen spray cryosurgery. Clin Exp Dermatol 1986; 11: 284-288.
63. Clark DP, Hanke CW. Electrosurgical treatment of rhinophyma. J Am Acad Dermatol 1990; 22: 831-837.
64. Eisen RF, Katz AE, Bohigian RK et al. Surgical treatment of rhinophyma with the Shaw scalpel. Arch Dermatol 1986; 122: 307-309.
65. Tromovitch TA, Glogau RG, Stegman SJ. The Shaw scalpel. J Dermatol Surg Oncol 1983; 9: 316-319.
66. el-Azhary RA, Roenigk RK, Wang TD. Spectrum of results after treatment of rhinophyma with the carbon dioxide laser. Mayo Clin Proc 1991; 66: 899-905.
67. 2 laser. Ear Nose Throat J 1997; 76: 740-743.
68. 2 laser vaporization for treatment of rhinophyma. Mayo Clin Proc 1987; 62: 676-680.
69. Shapshay SM, Strong MS, Anastasi GW et al. Removal of rhinophyma with the carbon dioxide laser: a preliminary report. Arch Otolaryngol 1980; 106: 257-259.
70. Hassard AD. Carbon dioxide laser treatment of acne rosacea and rhinophyma: how I do it. J Otolaryngol 1988; 17: 336-337.
71. Haas A, Wheeland RG. Treatment of massive rhinophyma with the carbon dioxide laser. J Dermatol Surg Oncol 1990; 16: 645-649.
72. 2 laser. Laryngoscope 1989; 99: 453-455.
73. Vidimos AT. Treatment of rhinophyma with the carbon dioxide laser. J Oral Max Surg 1991; 49: 1032.
74. Bohigian RK, Shapsay SM, Hybels RL. Management of rhinophyma with carbon dioxide laser: Lahey Clinic experience. Lasers Surg Med 1988; 8: 397-401.
75. Henning JPH, van Gemert MJC. Rhinophyma treated by argon laser. Lasers Surg Med 1983; 2: 211-215.
76. Dicken CH. Argon laser treatment of the red nose. J Dermatol Surg Oncol 1990; 16: 33-36.
77. Wenig BL, Weingarten RT. Excision of rhinophyma with Nd: YAG laser: a new technique. Laryngoscope 1993; 103: 101-103.
78. Orenstein A, Haik J, Tamir J et al. Treatment of rhinophyma with ER: YAG laser. Lasers Surg Med 2001; 29: 230-235.
79. Akpek EK, Merchant A, Pinar V et al. Ocular rosacea: patient characteristics and follow-up. Ophthalmol 1997; 104: 1863-1867.
80. Barnhorst DA Jr, Foster JA, Chern KC et al. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmol 1996; 103: 1880-1883.
81. Jenkins MS, Brown SI, Lempert SL et al. Ocular rosacea. Am J Ophthal 1979; 88: 618-622.
82. Bartholomew RS, Reid BJ, Cheesbrough MJ et al. Oxytetracycline in the treatment of ocular rosacea: a double-blind trial. Br J Ophthalmol 1982; 66: 386-388.
83. Frucht-Pery J, Sagi E, Hemo I et al. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol 1993; 116: 88-92.
84. Quarterman MJ, Johnson DW, Abele DC et al. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol 1997; 133: 49-54.
85. Garnis-Jones S. Psychological aspects of rosacea. J Cutan Med Surg 1998; 2 (Suppl. 4): 4-9.
86. Stewart TW, Savage D. Cosmetic camouflage in dermatology. Br J Dermatol 1972; 86: 530-532.